Following two (2) years of sluggish revenue performance, GlaxoSmithKline Consumer Plc (GLAXOSMITH) ended 2022FY with double digit topline expansion, anchored on the recovery of its pharmaceutical segment. Revenue from the pharmaceutical segment (c.66% of revenue surged 10.50% YoY to NGN16.75bn (vs NGN15.16bn in 2021FY), anchored on higher prices of prescription medicine as well as higher sales volume in the segment.
You May Also Like
Earnings Update | NESTLE | Q1:2020
- May 12, 2020
In its Q1:2020 financial scorecard, NESTLE recorded a marginal contraction in revenue (-0.90%) to NGN70.33bn from NGN70.97bn in…
Earnings Update | UBN | 2020FY
- April 1, 2021
UBN’s topline slightly decreased by 3.75% YoY to NGN166.55bn in 2020FY on the back of downtrend in interest…
Earnings Update | INTBREW | 9M:2020
- November 10, 2020
Unlike the first half of the year (where revenue was down 11.68% YoY), International Breweries Plc. (INTBREW) posted…
Earnings Update | FLOURMILL | H1:2021
- November 3, 2020
Building on the momentum gained in the first-quarter (year-end is March), Flour Mill of Nigeria Plc. (FLOURMILL) reported…
Earnings Update – UBA 2022FY A Decade’s Strongest Profit Growth.
- April 11, 2023
Amidst various macroeconomic event backdrop in the 20 African countries of operations, United Bank of Africa (UBA) ended…
Earnings Update – CUSTODIAN 2022FY Strong Growth in Interest Income Buoys Earnings.
- April 5, 2023
Custodian Investment Plc. (CUSTODIAN) in its 2022FY financial scorecard recorded a notable growth of 20.22% YoY in gross…